Johnson & Johnson (JNJ) on Tuesday reported positive topline results from the Phase 2b JASMINE study of nipocalimab in adults with systemic lupus erythematosus (SLE).
The study met its primary endpoint, with a statistically significant proportion of patients achieving the SLE Responder Index (SRI-4) composite response at Week 24 compared with placebo. Nipocalimab's safety and tolerability were consistent with previous Phase 2 studies, with no new safety signals identified.
Based on these results, J&J said it plans to initiate a Phase 3 program for nipocalimab in SLE.
On Monday, JNJ shares closed at $204.31, down 1.47%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.